Abstract
Background and aims Despite the introduction of pneumococcal conjugate vaccines (PCV), Streptococcus pneumoniae still remains an important cause of morbidity and mortality, especially among children under 5 years in sub-Saharan Africa. We sought to determine the distribution of lineages and antimicrobial resistance genes of S. pneumoniae, 5-6 years after the introduction of PCV10 in Ethiopia.
Methods Whole genome sequencing (WGS) was performed on 103 S. pneumoniae (86 from nasopharyngeal swabs, 4 from blood and 13 from middle ear swabs) isolated from children aged < 15 years at three health care facilities in Addis Ababa, Ethiopia from September 2016 to August 2017. Using the WGS data, serotypes were predicted, isolates were assigned to clonal complexes, Global Pneumococcal Sequence Clusters (GPSCs) were inferred and screening for alleles and mutations that confer resistance to antibiotics was performed using multiple bioinformatic pipelines.
Results The 103 S. pneumoniae isolates were assigned to 45 different GPSCs. The most common GPSCs were GPSC1 (sequence type (ST) 320, serotype 19A), 14.6%; GPSC268 (ST 6882 and Novel STs; serotypes 16F, 11A and 35A), 8.7% and GPSC10 (STs 2013, 230 and 8804; serotype 19A), 7.7%. Intermediate resistance to penicillin was predicted in 14.6% of the isolates and 27 different Penicillin Binding Protein (PBP) allele combinations were identified. Variations in sulfamethoxazole-trimethoprim (folA and/or folP), tetracycline (tetM, tetO or tetS/M) and macrolide (ermB and and/or mefA) resistance genes were predicted in 66%, 38.8% 19.4% of the isolates, respectively. Multidrug resistance (≥ 3 antibiotic classes) was observed in 18.4% (19/103) of the isolates and 78.9% of them were GPSC1 (ST320, serotype 19A).
Conclusion Five to six years after introduction of PCV10 in Ethiopia, the population of S. pneumoniae is quite diverse, with the most common lineage an MDR GPSC1 (ST 320, Serotype 19A), which is not covered by the PCV10. Continued assessment of the impact of PCV on the population structure of S. pneumoniae in Ethiopia is warranted.
Impact statement This study provides a detailed analysis of the genomic features of carriage and disease Streptococcus pneumoniae isolates from paediatric patients in Addis Ababa Ethiopia collected 5-6 years after introduction of PCV10 in the country. The study describes the distribution of serotypes, lineages, resistance genes and in silico predicted phenotypic antimicrobial resistance. The study highlights the predominance of multidrug resistant serotype 19A expressing GPSC1 (CC320). The findings underline the importance of continued genomic surveillance of pneumococcal carriage and disease to understand the selective pressure of vaccines on lineages and associated antimicrobial resistance.
Data Summary Genome sequences are deposited at ENA with accession numbers (ERR9796440-ERR9990857, ERR10419695-ERR10419739). The authors confirm all supporting data have been provided within the article or through supplementary data files.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was co-funded by the Bill and Melinda Gates Foundation (grant code OPP1034556), the Wellcome Sanger Institute (core Wellcome grants 098051 and 206194) and the US Centers for Disease Control and Prevention.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the AHRI/ All Africa Leprosy Rehabilitation and Training Hospital (ALERT) Ethical Review Committee (AAERC) (PO/017/15) and the National Research Ethics Review Committee (No. 310/194/17).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos